News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
256,048 Results
Type
Article (13725)
Company Profile (257)
Press Release (242066)
Section
Business (79133)
Career Advice (151)
Deals (13164)
Drug Delivery (28)
Drug Development (50129)
Employer Resources (31)
FDA (5625)
Job Trends (5106)
News (143539)
Policy (10012)
Tag
Academia (900)
Africa (145)
Allergies (30)
Alliances (21397)
Alzheimer's disease (679)
Antibody-drug conjugate (ADC) (31)
Approvals (5592)
Arizona (38)
Artificial intelligence (27)
Asia (16621)
Australia (2774)
Bankruptcy (96)
Best Places to Work (4336)
Biotechnology (215)
C2C Services and Suppliers (10604)
California (1146)
Canada (472)
Cancer (239)
Career advice (132)
CAR-T (32)
Cell therapy (89)
China (83)
Clinical research (38944)
Collaboration (79)
Colorado (34)
Compensation (33)
Connecticut (38)
COVID-19 (974)
Cystic fibrosis (58)
Data (162)
Diabetes (36)
Diagnostics (1153)
Earnings (28357)
Employer resources (29)
Europe (35621)
Events (45683)
Executive appointments (87)
FDA (5722)
Florida (114)
Funding (89)
Gene therapy (76)
Georgia (27)
GLP-1 (259)
Government (1050)
Healthcare (6503)
Hotbed/Location (184155)
Illinois (70)
Indiana (42)
Infectious disease (983)
Inflammatory bowel disease (77)
IPO (7125)
Job creations (860)
Job search strategy (128)
Kansas (52)
Layoffs (176)
Legal (1369)
Lung cancer (55)
Maryland (173)
Massachusetts (933)
Medical device (2512)
Medtech (2513)
Mergers & acquisitions (6029)
Metabolic disorders (124)
Michigan (36)
Minnesota (64)
Neuroscience (774)
New Jersey (304)
New York (374)
NextGen Class of 2024 (1975)
Non-profit (837)
North Carolina (319)
Northern California (506)
Obesity (72)
Ohio (60)
Opinion (86)
Parkinson's disease (29)
Patents (33)
Peanut (27)
Pennsylvania (263)
People (24676)
Pharmaceutical (41)
Phase I (13661)
Phase II (18107)
Phase III (11525)
Pipeline (67)
Postmarket research (842)
Preclinical (5760)
Press Release (30)
Rare diseases (100)
Real estate (1405)
Regulatory (7997)
Research institute (928)
South America (206)
Southern California (474)
Startups (1962)
Texas (103)
United States (4414)
Vaccines (126)
Washington State (147)
Weight loss (56)
Date
Today (78)
Last 7 days (361)
Last 30 days (1253)
Last 365 days (21434)
2024 (14707)
2023 (22413)
2022 (26822)
2021 (27810)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13746)
2016 (11845)
2015 (14360)
2014 (10393)
2013 (7489)
2012 (7533)
2011 (7617)
2010 (7433)
256,048 Results for "sangamo therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Despite Late-Stage Hemophilia Win, Sangamo Remains in Do-or-Die Situation
Sangamo and Pfizer’s hemophilia A gene therapy candidate scored a Phase III victory last week. However, with the genomic medicine company soon to run out of cash, Sangamo’s short-term prospects look bleak but not unsalvageable, analysts say.
July 31, 2024
·
3 min read
·
Tyler Patchen
Deals
Cash-Strapped Sangamo Gets Lifeline from Genentech in Potential $1.9B Neuro Deal
Sangamo Therapeutics announced Tuesday it secured an exclusive licensing agreement with Roche’s Genentech, which is paying $50 million in near-term upfront fees and milestone payments to develop novel genomic medicines for neurodegenerative diseases.
August 6, 2024
·
2 min read
·
Tyler Patchen
Business
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Sangamo Therapeutics, Inc., a genomic medicines company, reported business highlights and first quarter 2024 financial results.
May 9, 2024
·
17 min read
Business
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024.
May 2, 2024
·
1 min read
Drug Development
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Sangamo Therapeutics, Inc. today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.
May 9, 2024
·
4 min read
Deals
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics, Inc. today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an aggregate of 24,761,905 shares of its common stock.
March 22, 2024
·
4 min read
Business
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024.
March 12, 2024
·
1 min read
Drug Development
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc., a genomic medicine company, announced that the American Society of Gene & Cell Therapy has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual Meeting being held May 7-11, 2024, in-person in Baltimore, MD and in a virtual format.
April 22, 2024
·
8 min read
Business
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.
March 13, 2024
·
24 min read
Biotech Bay
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preclinical data from its proprietary adeno-associated virus (AAV) capsid variant, STAC-BBB.
March 13, 2024
·
10 min read
1 of 25,605
Next
